Patents by Inventor Kanehisa KOJOH
Kanehisa KOJOH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092836Abstract: The present invention provides a cyclic peptide which comprises the amino acid sequence represented by formula (I) X1-His-Pro-X4-Leu-X6-X7-X8-Ser-X10-His-Phe??(I) in the cycle and has an activity to specifically bind to human CTLA-4, wherein X1, X4, X6, X7, X8 and X10 are each independently any amino acid.Type: ApplicationFiled: September 30, 2020Publication date: March 21, 2024Applicant: GeneFrontier CorporationInventors: Kanehisa KOJOH, Kumiko TSUIHIJI, Shizue KATOH, Mikiko NAKAMURA
-
Patent number: 10865247Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: GrantFiled: February 20, 2020Date of Patent: December 15, 2020Assignees: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20200199235Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: February 20, 2020Publication date: June 25, 2020Applicants: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Patent number: 10640573Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: GrantFiled: October 5, 2018Date of Patent: May 5, 2020Assignees: GeneFrontier Corporation, Keio UniversityInventors: Akira Miyakoshi, Mikiko Nakamura, Kanehisa Kojoh, Satsuki Mochizuki, Yasunori Okada
-
Publication number: 20190233521Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: October 5, 2018Publication date: August 1, 2019Applicants: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa KOJOH, Akira MIYAKOSHI, Shizue KATOH, Kumiko TSUIHIJI, Yuki HAYAMI, Mikiko NAKAMURA, Toshinori NAKAYAMA, Chiaki IWAMURA
-
Publication number: 20190233541Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: ApplicationFiled: October 5, 2018Publication date: August 1, 2019Applicants: GeneFrontier Corporation, Keio UniversityInventors: Akira MIYAKOSHI, Mikiko NAKAMURA, Kanehisa KOJOH, Satsuki MOCHIZUKI, Yasunori OKADA
-
Patent number: 10329358Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.Type: GrantFiled: March 4, 2016Date of Patent: June 25, 2019Assignees: GeneFrontier Corporation, KEIO UNIVERSITYInventors: Akira Miyakoshi, Kanehisa Kojoh, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
-
Patent number: 10301618Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.Type: GrantFiled: February 19, 2016Date of Patent: May 28, 2019Assignee: GeneFrontier CorporationInventors: Kanehisa Kojoh, Takashi Kanamori, Shizue Katoh, Kumiko Tsuihiji
-
Publication number: 20180044435Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.Type: ApplicationFiled: March 4, 2016Publication date: February 15, 2018Applicants: GeneFrontier Corporation, KEIO UNIVERSITYInventors: Akira MIYAKOSHI, Kanehisa KOJOH, Satsuki MOCHIZUKI, Masayuki SHIMODA, Yasunori OKADA
-
Patent number: 9617533Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.Type: GrantFiled: September 25, 2015Date of Patent: April 11, 2017Assignees: GeneFrontier Corporation, The Univeristy of TokyoInventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
-
Patent number: 9493523Abstract: Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.Type: GrantFiled: May 6, 2011Date of Patent: November 15, 2016Assignee: GeneFrontier CorporationInventors: Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi, Mikiko Nakamura
-
Publication number: 20160304622Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: ApplicationFiled: October 14, 2014Publication date: October 20, 2016Applicants: GeneFrontier Corporation, Keio UniversityInventors: Akira MIYAKOSHI, Mikiko NAKAMURA, Kanehisa KOJOH, Satsuki MOCHIZUKI, Yasunori OKADA
-
Publication number: 20160168563Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: GeneFrontier CorporationInventors: Kanehisa KOJOH, Takashi KANAMORI, Shizue KATOH, Kumiko TSUIHIJI
-
Patent number: 9289742Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.Type: GrantFiled: April 26, 2013Date of Patent: March 22, 2016Assignee: GeneFrontier CorporationInventors: Kanehisa Kojoh, Takashi Kanamori, Shizue Katoh, Kumiko Tsuihiji
-
Publication number: 20160010079Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.Type: ApplicationFiled: September 25, 2015Publication date: January 14, 2016Inventors: Takashi KANAMORI, Yuki HAYAMI, Kanehisa KOJOH, Takuya UEDA, Kumiko TSUIHIJI, Tomoe FUSE, Mikiko NAKAMURA, Shizue KATO
-
Patent number: 9175327Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.Type: GrantFiled: May 3, 2011Date of Patent: November 3, 2015Assignees: GeneFrontier Corporation, The University of TokyoInventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
-
Patent number: 9133452Abstract: The present invention provides a method of producing a maturated oligonucleotide library, including a step of obtaining a terminal-modified product of a maturation target oligonucleotide library, including adding a tag sequence to the 5? terminus of the maturation target oligonucleotide library and an arrest sequence, which stalls translation elongation on a ribosome, to the 3? terminus of the maturation target oligonucleotide library, a step of transcribing the terminal-modified sequence product to give a transcript, and a step of in vitro translation for translating the transcript in vitro, wherein the maturation target oligonucleotide library is a random oligonucleotide library.Type: GrantFiled: June 23, 2011Date of Patent: September 15, 2015Assignees: The University of Tokyo, GeneFrontier CorporationInventors: Takuya Ueda, Takashi Kanamori, Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi
-
Publication number: 20150118237Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: April 23, 2013Publication date: April 30, 2015Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20130143773Abstract: The present invention provides a method of producing a maturated oligonucleotide library, including a step of obtaining a terminal-modified product of a maturation target oligonucleotide library, including adding a tag sequence to the 5? terminus of the maturation target oligonucleotide library and an arrest sequence, which stalls translation elongation on a ribosome, to the 3? terminus of the maturation target oligonucleotide library, a step of transcribing the terminal-modified sequence product to give a transcript, and a step of in vitro translation for translating the transcript in vitro, wherein the maturation target oligonucleotide library is a random oligonucleotide library.Type: ApplicationFiled: June 23, 2011Publication date: June 6, 2013Applicants: GENEFRONTIER CORPORATION, THE UNIVERSITY OF TOKYOInventors: Takuya Ueda, Takashi Kanamori, Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi
-
Publication number: 20130143299Abstract: Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.Type: ApplicationFiled: May 6, 2011Publication date: June 6, 2013Applicant: GENEFRONTIER CORPORATIONInventors: Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi, Mikiko Nakamura